A Real-World Comparison of BOIN versus Bayesian CRM in Phase I Dose-Finding Trials for Solid Tumors: A Single-Center Retrospective Study from 2020 to 2024
This single-center retrospective study of 78 patients across 15 phase I solid tumor trials (2020–2024) demonstrates that the Bayesian Optimal Interval (BOIN) design offers comparable dose-finding accuracy to the Continual Reassessment Method (CRM) while significantly outperforming it in operational efficiency, reducing study duration, protocol deviations, and manpower costs, making it particularly suitable for resource-constrained research centers.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.